Method for low-flow anesthesia based on sevoflurane with application of epiglottic i-gel duct

FIELD: medicine.

SUBSTANCE: induction into anesthesia is carried out by intravenous injection of 1% propofol solution at a dose of 1.5-2 mg/kg, up to 200 mg, and 0.005% fentanyl solution at a dose of 0.7-1 μg/kg. After reaching a sufficient depth of anesthesia with BIS 40-50 units, an epiglottic I-gel duct, a gastric tube through a special port on the duct are installed and the patient is transferred to lung ventilation in auxiliary modes: SIMV, PS; anesthesia is maintained by inhalation administration of sevoflurane at a dose of 1-2 volume percent with fresh gas flow of 0.8-1.2 l/min, via a semi-enclosed loop using a adsorber with soda lime; sevoflurane concentration is selected till a steady achievement of 0.6-0.8 MAK, analgesia is provided by intravenous administration of 0.005% solution of fentanyl; infusion therapy is carried out with physiological solution in a dose of 500-700 ml.

EFFECT: adequate level of sedation and analgesia, reduced time of anesthesia, reduced drug burden on the body, and a lower risk of anesthesia complications.

2 tbl

 



 

Same patents:

FIELD: medicine.

SUBSTANCE: anaesthetising patients with chronic pain syndrome undergoing a cyclophotocoagulation surgery involves the intravenous administration of the hormonal preparation dexamethasone in a dose of no more than 8 mg followed by the anxiolytic droperidol in a dose of no more than 2.5 mg 5 minutes prior to the operation before the peribulbar anaesthesia. A peripheral block in the form of the peribulbar anaesthesia involving administration of no more than 6 ml of a local anaesthetic follows. At the moment the surgical procedure starts, benzodiazepin, e.g. diazepam, is administered in a dose of no more than 5 mg.

EFFECT: achieving adequate anaesthesia in the given category of patients by blocking all the links of a pathological pain chain.

1 ex

FIELD: medicine.

SUBSTANCE: dexamethasone 8 mg and ketoprofen 100 mg is administered intravenously once prior to the operation. A lumbar plexus is blocked in a combination with a parasacral block and inserting perineural catheters to administer weak 0.2% Ropivacaine, local anaesthetic 20 ml. Paracetamol 1,000 mg is administered intravenously 30 minute before the operation is completed. After the operation is completed, the perineural catheter of the lumbar plexus is used to infuse 0.2% Ropivacaine 300 ml at 6-8 ml/hour for 4-5 days. Ketoprofen 100 mg is administered intramuscularly twice a day for 3 days. Through the perineural catheter of the parasacral plexus, 0.2% Ropivacaine 10 ml is administered twice every 12 hours.

EFFECT: method provides the adequate anaesthesia in the given category of patients by having an effect on primary pain components, as well as ensures the continuous and prolonged anaesthesia both intra-, and postoperatively, prevents the stable and chronic pain syndrome and the motor block of the extremities, reduces a rate of toxic complications.

1 ex

FIELD: medicine.

SUBSTANCE: preanaesthetic medication preceding gynaecological surgeries under general anaesthesia is ensured by prescribing diazepam 10mg, nefopam 10mg and ketoprofen 100mg intramuscularly 30-40 min before the surgery.

EFFECT: method enables reaching the sedative and analgesic effect of the preanaesthetic medication by the complementary action of preparations with no undesired side effects, requiring no time consumption and expensive equipment.

3 tbl, 2 ex

FIELD: chemistry.

SUBSTANCE: as active component pharmaceutical composition contains dihydrochloride of 9-(2-morpholine ethyl)-2-(4-fluorophenyl)imidazo[1,2-α]benzimidasol, and as additional substances - fillers, binding, sliding and film coatings, in quantities, given in the invention formula. Composition can be made in form of solid medication form, mainly in form of tablets and capsules.

EFFECT: obtained solid medication forms satisfy the requirements of the State Pharmacopoeia.

7 cl, 2 dwg, 3 tbl, 14 ex

FIELD: medicine.

SUBSTANCE: at the initial stage of the intraoperative period, immediately before the local anaesthesia and the femoral artery puncture, ketorolac tromethamine is administered intravenously as an analgesic, and propofol as a sedative agent. Ketorolac tromethamine is administered in a dose of 15-75 mg, while propofol is administered in a dose of 50-250 mg.

EFFECT: method prevents developing pain and psychoemotional responses caused by the given interventions, including postoperatively by the fast development of the adequate analgesic effect accompanied by the controlled sedation level.

1 tbl, 10 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to organic chemistry, namely to benzimidazole derivatives of general formula (I) and to their pharmaceutically acceptable salts, mixed stereoisomers and enantiomers, wherein R1 is L1C(O)OL2C(O)OT; R2 is unsubstituted C1-C10alkyl; L1 is a bond; L2 is unsubstituted C2-C10alkylene; T is C1-C10alkyl. Also, the invention refers to a pharmaceutical composition of the compound of formula (I) and a method of anaesthetising on the basis of using the compound of formula (I).

EFFECT: there are prepared new imidazole derivatives effective as an anaesthetising agent.

15 cl, 9 dwg, 15 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to a new compound, namely to (S)-enantiomer of 1'-{[5-(trifluoromethyl)furan-2-yl]methyl}spiro[furo[2,3-f][1,3]benzodioxol-7,3'-indole]-2'(1'H)-one of formula (I), and a method for preparing it which is effective for treating diseases and conditions, such as pain, an intensity of which can be reduced or relieved by modulating potential-dependent sodium channel gatings.

EFFECT: invention refers to the pharmaceutical composition of the above compound, methods of treating and a method of relieving an ion flux through the potassium channel gating in a cell.

10 cl, 5 tbl, 6 dwg, 11 ex

FIELD: biotechnology.

SUBSTANCE: aqueous composition for anaesthesia is proposed, which comprises propofol as an active agent, the PEG-660-12-hydroxystearate as a solubiliser, benzyl alcohol, or chloroethanol or parabens as preservative, the tocopherol and arginine or glycine at a specific content of components wt %. The GABA agonists can be additionally added to the composition, e.g. aminophenyl-butyric acid, local anesthetics such as lidocaine, alpha-2-adrenoceptor agonists such as xylazine. The method is proposed for implementing anaesthesia comprising administering to a patient of an effective amount of the claimed composition.

EFFECT: invention provides low toxicity of dosage form and high efficiency.

5 cl, 3 tbl, 1 ex

FIELD: medicine.

SUBSTANCE: what is involved is infusion therapy with crystalloid solutions at 15 ml/kg of a patient's body weight. That is followed by puncturing and catheterising an epidural space at the level of ThVII-ThVIII according to the standard practice and introducing a test dose of 2% lidocaine 3 ml. If observing no signs of intrathecal introduction of local anaesthetics 10 minutes later, a basic dose containing 0.75-1% naropin 10 ml or 0.25-0.5% marcaine 10 ml and clofelin 3-5 mcg/kg is introduced. Total intravenous anaesthesia follows 20 minutes after pre-medication with atropine 0.01 mg/kg, 1% diphenylhydramine 1 ml and relanium 10 mg and urethral catheterisation. A narcosis is induced with propofol in a dose of 2 mg/kg. Anaesthesia is maintained with propofol 2-4 mg/kg·h. After that, within the first hour following the detoxification, naloxone 12 mg is introduced intravenously; a naloxone measurement rate is supposed to make 0.8 mg/h for 4-5 following hours of general anaesthesia. The repeated introduction of 0.75-1% naropin 6 ml or 0.25-0.5% marcaine 6 ml and clofelin 2-3 mcg/kg into the epidural space is performed 90 minutes later. After the procedure is terminated, and the patient recovers, prolonged epidural analgesia is conducted by introducing 0.2% naropin 10 ml and clofelin 1 mcg/kg into the epidural space every 4 hours for 24-48 hours.

EFFECT: method provides safety of ultrafast opioid detoxification and prolongs the remission in the given category of patients.

1 ex

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely to anaesthesiology and resuscitation, and may be used in epidural anaesthesia. That is ensured by administering slowly intravenously a basic dose of the local anaesthetic: 0.2-1% naropin or 0.2-0.5% marcaine, or 1-2% lidocaine; 1% Sol. Nicotini acidi 1% - 0.5-1 ml into the epidural space 10-20 minutes later. After 5-10 minutes, nicotine test results are visually evaluated by determining a clear interface of skin colour - hyperemic and normal - along an axillary line from both sides. The normal skin interface corresponds to the sympathetic block.

EFFECT: method provides higher accuracy and simplification of measuring the sympathetic block.

1 ex

FIELD: medicine.

SUBSTANCE: invention refers to veterinary science and aims at controlling demodectic mange in cattle. As an insectoacaricide, a composition is used in the following mixture ratio, wt %: abamectin - 0.1; fipronil - 0.5; dimehyl sulphoxide - 10; ethyl cellulose - 30-40; polyethylene glycol - 1,500 - 16; isopropyl alcohol - the rest up to 100. The composition is used by local applications on the affected areas of the animal's skin.

EFFECT: method enables increasing the therapeutic effectiveness in treating demodectic mange in cattle.

1 tbl, 3 ex

FIELD: veterinary medicine.

SUBSTANCE: insecticidal-acaricidal agent is used as a composition with the following ratio of components, wt %: abamectin - 0.1; fipronyl - 0.5; dimethyl sulfoxide - 10; ethyl-cellulose - 30-40; polyethylene glycol-1500 - 16; isopropyl alcohol - the rest to 100. The composition is used by the method of application to the region of dewlap, shoulder, hip and abdomen in a dose of 20 ml per animal.

EFFECT: method enables to increase the efficiency of protection of cattle from ixodic ticks.

1 tbl, 3 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: group of inventions refers to antiseptic compositions and applicable for disinfection of surfaces, such as body surfaces, and for treatment of infection-related conditions. As active ingredients, an antiseptic composition contains menthol and silver ions, and a pharmaceutically acceptable carrier. The silver ion concentration in the composition makes from 0.25 mM to 0.6 mM, whereas the menthol concentration makes from 0.64 mM to 6.4 mM. What is also presented is an antiseptic kit containing the above composition and a packaging material. Other embodiments involve a method for producing the above antiseptic composition, a method for reducing the silver ion concentration in the antiseptic composition and a method for increasing the antiseptic activity of the above composition.

EFFECT: using the group of inventions provides producing the antiseptic composition that is ensured by the synergetic effect of menthol and silver ions in the used concentrations in relation to various bacteria.

16 cl, 5 tbl, 6 ex, 4 dwg

FIELD: medicine.

SUBSTANCE: invention represents an antibacterial pharmaceutical composition containing clotrimazole, propylene glycol, macrogol 400, macrogol 1,500, macrogol 4,000, poloxamer 338, cetostearyl alcohol, macrogol 20 cetostearyl alcohol, disodium edetate, purified water with the ingredients of the compositions taken in certain proportions, g/100 g.

EFFECT: higher antibacterial and antifungal action.

3 cl, 3 dwg, 5 tbl

FIELD: medicine.

SUBSTANCE: treating bronchial asthma is ensured by superior laryngeal nerve anaesthesia with 0.5% Novocaine mixed with 96° rectified ethyl alcohol for the purpose of bronchial spasmolysis in bronchial asthma.

EFFECT: method enables reducing an episode of bronchial asthma quickly and for long duration by interrupting a flow of pathologic nerve impulses along the superior laryngeal nerve.

2 tbl, 1 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to a melanin production inhibitor and a topical preparation, such as a cosmetic preparation. The invention represents a melanin production inhibitor containing a compound presented by the following general formula (1) (except clotrimazole), and/or its pharmacologically acceptable salt, as well as a topical preparation applicable for melanin production inhibition and containing the melanin production inhibitor.

EFFECT: invention provides the excellent inhibitory effect on melanin production; it is highly safe, consequently, applicable as an ingredient of the topical preparation.

16 cl, 51 ex, 12 tbl

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely to thoracic surgery, and can be used to close defects of the lower one-third of the oesophagus. A laparotomy and a sagittal diaphragmotomy are performed. The oesophageal wall defect is closed with a single-layer uninterrupted absorbable mass suture. The suture is started from the proximal end of the defect with the first knot tightened into the oesophageal lumen. A fundoplication cuff is created with covering the suture with the stomach. One of the gastric walls is fixed by interrupted sutures surrounding the closed oesophageal defect to form a cavity between the closed oesophageal defect and the gastric wall. The cavity is filled with Coletex ADL hydrogel tissue. The fundoplication cuff is fixed by interrupted sutures circularly to the diaphragm. The pleural spaces, mediastinal and subphrenic space are drained.

EFFECT: method provides reducing the time of recovery, reducing a probability of postoperative complications and faster rehabilitation by forming the reliable sutures, long bactericidal effect on the suture area, dividing the pleural space and abdominal cavity.

1 ex

FIELD: medicine.

SUBSTANCE: composition 16-21ml consisting of a mixture of therapeutic preparations: Dona glucosamine sulphate 3.0 ml; ChondroGuard, or Mucosatum, or Chondrolon chondroitin sulphate - 2.0 ml; Alflutop 2.0 ml; Actovegin 4.0-5.0 ml; glucocorticosteroids Depo-Medrol 1.0-2.0 ml in the concentration of 40 mg/ml, or Diprospane 1.0-2.0 ml in the concentration of 7 mg/ml, or Metipred 1.0-2.0 ml in the concentration of 62.5 mg/ml; vitamins B1, B6, B12 Combilipen 2.0 ml, or Milgamma 2.0 ml, or Neurobion 3.0 ml; 95% or 70% ethanol 2.0-4.0 ml, is administered into a pathologically changed region. That is immediately followed by exposing the pathologically changed region and adjoining segments to a session of A shock-wave therapy in the following mode: pressure 1.2 - 4.0 bar, frequency 7-12 Hz, beat quantity 8000-14000 for 20-40 minutes. The complex procedures are performed within the course of 1-6 times every 7-10 days.

EFFECT: method enables the direct exposure on the pathologically changed region to achieve the optimum concentration of drug preparations therein with avoiding systemic prescription and preventing a risk of side effects.

3 tbl, 2 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to pharmaceutical industry and represents a skin care agent possessing the antifungal properties, containing propolis, ethanol, and a sulphur-containing component, differing the fact that the sulphur-containing component contains elemental nanodispersed sulphur with the components of the agent taken in certain amounts, wt %.

EFFECT: invention provides extending the range of products possessing a wide spectrum of fungicidal action, and promotes the tissue regeneration processes.

3 cl, 3 ex, 1 tbl

FIELD: veterinary medicine.

SUBSTANCE: method comprises administering an agent containing gentamicin, gamavit, sodium benzoate, potassium sorbate and propylene glycol. The agent is used in intrauterine mode 2 times a day for 7-10 days at a dose of 5-10 ml to cat and 10-20 ml to dog.

EFFECT: method comprises high therapeutic efficacy in endometritis of cats and dogs.

1 ex

FIELD: medicine.

SUBSTANCE: oral pharmacological composition for treating secondary amyloidosis contains alkaloid curcumin, betulin and piperine taken in certain proportions.

EFFECT: composition is effective for treating secondary amyloidosis.

Up!